PTT 936
Alternative Names: PTT-936Latest Information Update: 19 Jun 2024
At a glance
- Originator Pyrotech Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action ALPK1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics and adverse event data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 06 Feb 2024 Pyrotech Therapeutics plans a phase I/IIa trial in Solid tumours (Monotherapy, Combination therapy, Metastatic disease, Late-stage disease) in January 2024 (NCT06244992)
- 26 Jan 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT06244992)